Rosetta Puts Blood-Based Cancer Screen on Back Burner to Refocus on miRNA Diagnostics (GenomeWeb News)

Rosetta Genomics this month announced that it has scaled back its work on a serum-based colon cancer-screening assay based on microRNA biomarkers, less than a year after the company said that commercialization of the test, dubbed miRscreen Colon, had become its top priority.